Evotec (EVO) Set to Announce Quarterly Earnings on Wednesday

Evotec (NASDAQ:EVOGet Free Report) is scheduled to announce its earnings results before the market opens on Wednesday, November 6th. Analysts expect the company to announce earnings of ($0.09) per share for the quarter.

Evotec Stock Down 2.5 %

Shares of NASDAQ EVO opened at $3.86 on Thursday. Evotec has a fifty-two week low of $2.85 and a fifty-two week high of $12.00. The firm’s 50-day simple moving average is $3.41 and its 200 day simple moving average is $4.36. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.73 and a current ratio of 1.83.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the stock. HC Wainwright cut their price objective on shares of Evotec from $11.00 to $8.00 and set a “buy” rating on the stock in a research note on Thursday, August 15th. Deutsche Bank Aktiengesellschaft cut shares of Evotec from a “hold” rating to a “sell” rating in a research note on Thursday, August 8th. Morgan Stanley cut shares of Evotec from an “overweight” rating to an “equal weight” rating and cut their price objective for the company from $15.00 to $6.00 in a research note on Monday, July 29th. Finally, Jefferies Financial Group cut shares of Evotec from a “buy” rating to a “hold” rating and dropped their price target for the stock from $8.70 to $3.80 in a research report on Monday, October 7th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $5.93.

View Our Latest Research Report on Evotec

About Evotec

(Get Free Report)

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women’s health.

See Also

Earnings History for Evotec (NASDAQ:EVO)

Receive News & Ratings for Evotec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evotec and related companies with MarketBeat.com's FREE daily email newsletter.